Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib Plus Obinutuzumab in R/R Follicular Lymphoma
NCT03890289Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall Response Rate at 6 months. Started Oct 2019; status: terminated.
02
Drugs
idelalisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03890289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890289.